Bausch + Lomb eyes AU$1.2 billion in IPO

Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO).
Read More

Eyecare spin-off Bausch + Lomb files for IPO

Almost 18 months since its parent company announced Bausch + Lomb (B+L) would be spun off as a pure-play eye health company, the entity has filed for an initial public offering (IPO) on the New York and Toronto stock exchanges.
Read More

Rethinking what’s possible with the enVista IOL

Bausch + Lomb’s latest version of the enVista monofocal recently became available to Australian and New Zealand surgeons along with a new pre-loaded delivery system. Early adopters discuss making it a go-to IOL and how it’s offering increased depth-of-field in many patients. Read More